ShafiT, MullangiS, JaarBG, SilberH: Autonomic dysfunction as a mechanism of intradialytic blood pressure instability. Semin Dial, 2017; 30:537–544.
2.
GalesBJ, GalesMA: Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother, 2007; 41:314–318.
3.
ShibaoC, OkamotoLE, GamboaA, et al.: Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension, 2010; 56:847–851.
4.
YamamotoT, SakakibaraR, YamanakaY, et al.: Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug?. Clin Auton Res, 2006; 16:296–298.
5.
VargaB, CsonkaÁ, CsonkaA, MolnárJ, AmaralL, SpenglerG: Possible biological and clinical applications of phenothiazines. Anticancer Res, 2017; 37:5983–5993.
6.
KristiansenJE, DastidarSG, PalchoudhuriS, et al.: Phenothiazines as a solution for multidrug resistant tuberculosis: from the origin to present. Int Microbiol, 2015; 18:1–12.
7.
KlitgaardJK, SkovMN, KallipolitisBH, KolmosHJ: Reversal of methicillin resistance in Staphylococcus aureus by thioridazine. J Antimicrob Chemother, 2008; 62:1215–1221.
8.
DenisK, Le BrisM, Le GuennecL, et al.: Targeting type IV pili as an antivirulence strategy against invasive meningococcal disease. Nat Microbiol, 2019; 4:972–984.
9.
RobbinsN, KochSE, TranterM, RubinsteinJ: The history and future of probenecid. Cardiovasc Toxicol, 2012; 12:1–9.
10.
DuL, EmpeyPE, JiJ, et al.: Probenecid and N-acetylcysteine prevent loss of intracellular glutathione and inhibit neuronal death after mechanical stretch injury in vitro. J Neurotrauma, 2016; 33:1913–1917.
11.
PerwitasariO, YanX, JohnsonS, et al.: Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother, 2013; 57:475–483.
12.
AhmedMU, BennettDJ, HsiehTC, DoonanBB, AhmedS, WuJM: Repositioning of drugs using open-access data portal DTome: a test case with probenecid (review). Int J Mol Med, 2016; 37:3–10.
13.
DossiE, BlauwblommeT, MoulardJ, et al.: Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy. Sci Transl Med, 2018; 10:eaar3796.
14.
AquilinoMS, Whyte-FagundesP, ZoidlG, CarlenPL: Pannexin-1 channels in epilepsy. Neurosci Lett, 2019; 695:71–75.
15.
BlierP, WardNM: Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry, 2003; 53:193–203.
16.
BantickRA, DeakinJF, GrasbyPM: The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol, 2001; 15:37–46.
17.
LutsepHL: Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke. Curr Drug Targets CNS Neurol Disord, 2005; 4:119–120.
18.
YaffeD, ForrestLR, SchuldinerS: The ins and outs of vesicular monoamine transporters. J Gen Physiol, 2018; 150:671–682.
19.
KolmusK, TavernierJ, GerloS: β2-adrenergic receptors in immunity and inflammation: stressing NF-κB. Brain Behav Immun, 2015; 45:297–310.
20.
IzeboudCA, MonshouwerM, van MiertAS, WitkampRF: The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-alpha and IL-6 in vitro and in vivo. Inflamm Res, 1999; 48:497–502.
21.
GriffinÉW, YsselJD, O'NeillE, et al.: The β2-adrenoceptor agonist clenbuterol reduces the neuroinflammatory response, neutrophil infiltration and apoptosis following intra-striatal IL-1β administration to rats. Immunopharmacol Immunotoxicol, 2018; 40:99–106.
22.
YaoY, WangJB, XinMM, et al.: Balance between inflammatory and regulatory cytokines in systemic lupus erythematosus. Genet Mol Res, 2016; 15:gmr7626.
23.
RafteryEB, DenmanAM: Systemic lupus erythematosus syndrome induced by practolol. Br Med J, 1973; 2:452–455.
24.
Bilewicz-StebelM, MiziołekB, Bergler-CzopB, StańkowskaA: Drug-induced subacute cutaneous lupus erythematosus caused by a topical beta blocker—timolol. Acta Dermatovenerol Croat, 2018; 26:44–47.
BoychukCR, HalmosKC, SmithBN: Diabetes induces GABA receptor plasticity in murine vagal motor neurons. J Neurophysiol, 2015; 114:698–706.
27.
TianJ, DangH, HuA, XuW, KaufmanDL: Repurposing lesogaberan to promote human islet cell survival and β-cell replication. J Diabetes Res, 2017; 2017:6403539.
28.
van der Horst-SchriversANA, SluiterWJ, KruizingaRC, et al.: The incidence of consecutive manifestations in VonHippel-Lindau disease. Fam Cancer, 2019 [Epub ahead of print]; DOI: 10.1007/s10689-019-00131-x.
29.
CrespigioJ, BerbelLCL, DiasMA, et al.: Von Hippel-Lindau disease: a single gene, several hereditary tumors. J Endocrinol Invest, 2018; 41:21–31.
30.
XieL, XiaoK, WhalenEJ, et al.: Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal, 2009; 2:ra33.
31.
RotterA, de OliveiraZNP: Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges, 2017; 15:1185–1190.
32.
AlbiñanaV, EscribanoRMJ, SolerI, et al.: Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis, 2017; 12:122.
33.
BilskiAJ, HallidaySE, FitzgeraldJD, WaleJL: The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol, 1983; 5:430–437.
34.
FilippiM, WolinskyJS, Comi G, CORAL Study Group: Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol, 2006; 5:213–220.
35.
AharoniR, KayhanB, BrennerO, DomevH, LabunskayG, ArnonR: Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther, 2006; 318:68–78.
36.
AharoniR, SonegoH, BrennerO, EilamR, ArnonR: The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett, 2007; 112:110–119.
37.
HauptS, GilE, TiroshR, KlingerE, GadA, RubinsteinA: Regional peptide uptake study in the rat intestinal mucosa: glatiramer acetate as a model drug. Pharm Res, 2002; 19:832–837.
38.
WangY, LiS, LiC: Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. Med Sci Monit, 2019; 25:1017–1023.
39.
AbdouAG, MaraeeA, YassienH, SarhanM: Immunohistochemistry of Janus kinase 1 (JAK1) expression in vitiligo. J Pathol Transl Med, 2018; 52:363–368.
40.
RothsteinB, JoshipuraD, SaraiyaA, et al.: Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol, 2017; 76:1054–1060.e1.
41.
CraiglowBG, KingBA: Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol, 2015; 151:1110–1112.
42.
RelkeN, GooderhamM: The use of Janus kinase inhibitors in vitiligo: a review of the literature. J Cutan Med Surg, 2019; 23:298–306.
43.
SultanaS, BhatnagarA, RawatH, et al.: Pulmonary delivery of nanosized alendronate for decorporation of inhaled heavy metals: formulation development, characterization and gamma scintigraphic evaluation. Pharm Dev Technol, 2014; 19:623–633.
44.
Ezzati Nazhad DolatabadiJ, HamishehkarH, ValizadehH: Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm, 2015; 41:1431–1437.
45.
UenoM, MaenoT, NishimuraS, et al.: Alendronate inhalation ameliorates elastase-induced pulmonary emphysema in mice by induction of apoptosis of alveolar macrophages. Nat Commun, 2015; 6:6332.
46.
GulamhuseinAF, HirschfieldGM: Pathophysiology of primary biliary cholangitis. Best Pract Res Clin Gastroenterol, 2018; 34–35:17–25.
47.
Alcocer-GómezE, Casas-BarqueroN, WilliamsMR, et al.: Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in major depressive disorder. Pharmacol Res, 2017; 121:114–121.
48.
AlmishriW, ShaheenAA, SharkeyKA, SwainMG: The antidepressant mirtazapine inhibits hepatic innate immune networks to attenuate immune-mediated liver injury in mice. Front Immunol, 2019; 10:803.
49.
Philogene-KhalidHL, SimmonsSJ, MuschampJW, RawlsSM: Effects of ceftriaxone on conditioned nicotine reward in rats. Behav Pharmacol, 2017; 28:485–488.
50.
StennettBA, FrankowskiJC, PerisJ, KnackstedtLA: Ceftriaxone reduces alcohol intake in outbred rats while upregulating xCT in the nucleus accumbens core. Pharmacol Biochem Behav, 2017; 159:18–23.
51.
LaCrosseAL, HillK, KnackstedtLA: Ceftriaxone attenuates cocaine relapse after abstinence through modulation of nucleus accumbens AMPA subunit expression. Eur Neuropsychopharmacol, 2016; 26:186–194.
52.
TaiCH, BellesiM, ChenAC, et al.: A new avenue for treating neuronal diseases: ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behav Brain Res, 2019; 364:149–156.
